Aclaris therapeutics, inc. (ACRS)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Sep'14
Revenue, net

1,407

-3,884

983

5,865

1,263

239

1,118

3,676

1,118

-

684

-

-

-

-

-

-

-

-

-

-

-

Costs and expenses:
Revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Cost of revenue

-

-

-

-

1,207

1,114

1,067

1,181

967

-

453

-

-

-

-

-

-

-

-

-

-

-

Cost of revenue

1,269

-

826

2,703

-

-

-

1,181

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gross profit

-

-

-

-

-

-

-

-

-

-

231

-

-

-

-

-

-

-

-

-

-

-

Research and development

9,444

11,451

16,183

17,622

19,643

18,062

15,189

13,984

13,606

9,203

10,864

7,965

7,772

6,943

7,162

9,836

9,535

2,402

9,407

1,793

1,737

2,097

Sales and marketing

-

-

112

7,177

-

-23,494

63

12,368

11,233

-7,098

3,557

2,188

1,438

-

-

-

-

-

-

-

-

-

General and administrative

6,200

4,976

6,726

7,990

7,464

5,069

6,141

8,121

6,260

5,520

4,566

5,142

3,720

1,389

3,650

3,153

3,604

2,400

1,233

803

892

565

Goodwill impairment

-

-

-

18,504

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of definite-lived intangible

-

-

-

1,660

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total costs and expenses

16,913

7,468

23,847

55,656

28,314

751

22,460

35,654

32,066

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

-

-

-

-

-

-

-

-

-

-

18,987

15,295

12,930

11,627

10,812

12,989

13,139

4,802

10,640

2,596

2,629

2,662

Loss from operations

-15,506

-11,352

-22,864

-49,791

-27,051

-512

-21,342

-31,978

-30,948

-7,380

-18,756

-15,295

-12,930

-11,627

-10,812

-12,989

-13,139

-4,802

-10,640

-2,596

-2,629

-2,662

Other income (expense), net

178

-1,895

-274

-85

-230

487

710

760

719

678

564

457

371

152

118

118

100

-

-

-

-

-

Loss from continuing operations

-15,328

-

-23,138

-

-27,281

-

-20,632

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from discontinued operations

-258

-

-32,181

-

-10,284

-

-12,108

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8

2

6

-

Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5

Net loss

-15,586

-18,594

-55,319

-49,876

-37,565

-38,551

-32,740

-31,218

-30,229

-22,934

-18,192

-14,838

-12,559

-11,475

-10,694

-12,871

-13,039

-4,714

-10,632

-2,594

-2,623

-2,657

Accretion of convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

213

1,020

676

657

479

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-14,838

-12,559

-

-

-

-

-4,927

-11,652

-3,270

-3,280

-3,136

Net loss per share, basic and diluted

-0.37

-0.44

-1.34

-1.21

-0.91

-0.98

-1.06

-1.01

-0.98

-0.77

-0.63

-0.56

-0.48

-0.48

-0.50

-0.62

-0.65

4.46

-5.12

-1.52

-1.61

-1.75

Weighted average common shares outstanding, basic and diluted (in shares)

41,618

41,407

41,364

41,274

41,248

38,826

30,982

30,944

30,885

30,899

28,834

26,594

26,080

23,412

21,415

20,663

20,171

17,963

2,274

2,154

2,034

1,794

Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities, net of tax of $0

60

-13

-23

30

34

34

65

111

-65

-128

63

-4

-52

-39

-12

14

142

-155

1

3

3

-3

Foreign currency translation adjustments

53

-52

14

27

-14

14

7

28

-17

-5

-10

87

72

-176

-43

-16

10

-

-

-

-

-

Total other comprehensive income (loss)

113

-65

-9

57

20

48

72

139

-82

-133

53

83

20

-215

-55

-2

152

-150

1

3

3

-3

Comprehensive loss

-15,473

-18,659

-55,328

-49,819

-37,545

-38,503

-32,668

-31,079

-30,311

-23,067

-18,139

-14,755

-12,539

-11,690

-10,749

-12,873

-12,887

-4,864

-10,631

-2,591

-2,620

-2,660

Product sales
Revenue, net

-

-

-

4,979

-

-

-

1,533

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contract research
Revenue, net

1,189

1,095

983

886

1,263

1,272

1,118

1,143

1,118

-

-

-

-

-

-

-

-

-

-

-

-

-

Other revenue
Revenue, net

218

-

-

-

-

-

-

1,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-